A. Garcia-Lora

发表

Role of altered expression of HLA class I molecules in cancer progression.

F. Garrido, F. Ruiz-Cabello, R. Méndez, 2007, Advances in experimental medicine and biology.

MHC class I antigens, immune surveillance, and tumor immune escape

Federico Garrido, F. Garrido, A. Garcia-Lora, 2003, Journal of cellular physiology.

MHC Class I Antigens and the Tumor Microenvironment

F. Garrido, F. Ruiz-Cabello, N. Aptsiauri, 2013 .

The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis

F. Garrido, A. Garcia-Lora, I. Algarra, 2008, BMC Cancer.

Bmc Cancer

F. Garrido, A. Garcia-Lora, I. Algarra, 2022 .

Identification of the protein components of protein-bound polysaccharide (PSK) that interact with NKL cells

E. Jiménez, F. Garrido, A. Garcia-Lora, 2005, Cancer Immunology, Immunotherapy.

Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line

F. Garrido, A. Garcia-Lora, Marisol Martinez, 2002, Cancer Immunology and Immunotherapy.

Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line

F. Garrido, A. Garcia-Lora, S. Pedrinaci, 2001, Cancer Immunology, Immunotherapy.

Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity

F. Garrido, A. Garcia-Lora, I. Algarra, 2009, Cancer Immunology, Immunotherapy.

Immunotherapy eradicates metastases with reversible defects in MHC class I expression

F. Garrido, A. Garcia-Lora, I. Algarra, 2011, Cancer Immunology, Immunotherapy.

Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine

F. Garrido, A. Garcia-Lora, I. Algarra, 2020, Cancers.

The pro-oxidant buthionine sulfoximine (BSO) reduces tumor growth of implanted Lewis lung carcinoma in mice associated with increased protein carbonyl, tubulin abundance, and aminopeptidase activity

A. Garcia-Lora, A. Quesada, F. Vargas, 2014, Tumor Biology.

Effect of thyroid hormone–nitric oxide interaction on tumor growth, angiogenesis, and aminopeptidase activity in mice

A. Garcia-Lora, A. Quesada, A. Osuna, 2014, Tumor Biology.

Immunoselection by T lymphocytes generates repeated MHC class I‐deficient metastatic tumor variants

F. Garrido, F. Ruiz-Cabello, A. Garcia-Lora, 2001, International Journal of Cancer.

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank

F. Garrido, F. Ruiz-Cabello, R. Méndez, 2009, Cancer Immunology, Immunotherapy.

Tumour immunology, vaccination and escape strategies.

F. Garrido, A. Garcia-Lora, I. Algarra, 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab

F. Garrido, A. Garcia-Lora, G. Garrido, 2017, Front. Pharmacol..

MHC heterogeneity and response of metastases to immunotherapy

F. Garrido, A. Garcia-Lora, I. Algarra, 2021, Cancer and Metastasis Reviews.

Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response

F. Novelli, A. Garcia-Lora, R. Accolla, 2014, Pancreas.

HLA Class I Expression in Human Cancer

N. Aptsiauri, T. Cabrera, A. Garcia-Lora, 2013 .

MHC Class I Antigens In Malignant Cells

N. Aptsiauri, T. Cabrera, A. Garcia-Lora, 2013, SpringerBriefs in Cancer Research.

MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models

A. Garcia-Lora, I. Algarra, Irene Romero, 2020, Cancer Immunology.

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells

F. Garrido, A. Garcia-Lora, I. Algarra, 2012, The Journal of pathology.

MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components

F. Garrido, A. Garcia-Lora, I. Algarra, 2003, International journal of cancer.

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

F. Garrido, A. Garcia-Lora, I. Algarra, 2010, Cancer Immunology, Immunotherapy.

MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.

F. Garrido, A. Garcia-Lora, I. Algarra, 2012, Carcinogenesis.

MHC class I antigens and immune surveillance in transformed cells.

F. Garrido, M. López-Nevot, F. Ruiz-Cabello, 2007, International review of cytology.

Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.

F. Garrido, A. Garcia-Lora, Irene Romero, 2014, Cancer research.

T lymphocytes restrain spontaneous metastases in permanent dormancy.

F. Garrido, A. Garcia-Lora, I. Algarra, 2014, Cancer research.

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape

Federico Garrido, F. Garrido, F. Ruiz-Cabello, 2004, Cancer Immunology, Immunotherapy.

Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms

F. Garrido, L. E. Fernández, A. Garcia-Lora, 2014, Oncogene.

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype

F. Garrido, N. Aptsiauri, A. Garcia-Lora, 2016, International journal of cancer.

Overview of MHC Class I Antigens

N. Aptsiauri, T. Cabrera, A. Garcia-Lora, 2013 .

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

F. Garrido, L. Real, N. Aptsiauri, 2008, Cancer Immunology, Immunotherapy.

International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain

G. Pawelec, F. Garrido, N. Aptsiauri, 2007, Cancer Immunology, Immunotherapy.

Cancer immune escape: implications for immunotherapy, Granada, Spain, October 3–5, 2011

F. Garrido, N. Aptsiauri, T. Cabrera, 2012, Cancer Immunology, Immunotherapy.

MHC Class I Expression in Experimental Mouse Models of Cancer: Immunotherapy of Tumors with Different MHC-I Expression Patterns

N. Aptsiauri, T. Cabrera, A. Garcia-Lora, 2013 .

MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy

F. Garrido, A. Garcia-Lora, I. Algarra, 2018, Front. Immunol..

‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells

F. Garrido, N. Aptsiauri, A. Garcia-Lora, 2014 .

A novel preclinical murine model of immune-mediated metastatic dormancy

F. Garrido, A. Garcia-Lora, Irene Romero, 2014, Oncoimmunology.

Potential Therapeutic Approaches for Increasing Tumor Immunogenicity by Upregulation of Tumor HLA Class I Expression

N. Aptsiauri, T. Cabrera, A. Garcia-Lora, 2013 .

A new extract of the plant calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation

F. Garrido, A. Garcia-Lora, I. Algarra, 2006, BMC Cancer.

Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response

F. Garrido, M. López-Nevot, C. Cabrera, 2007, International journal of cancer.